In vitro reactivation of trichlorfon-inhibited butyrylcholinesterase using HI-6, obidoxime, pralidoxime and K048

References

• P Taylor. Development of acetylcholinesterase inhibitors in the therapy of Alzheimer's disease. Neurology 1998; 51:30–35.
   PubMed Web of Science ®Google Scholar
• IG McKetih. The clinical trial protocol of the metrifonate in Alzheimer's trial (MALT). Dement Geriatr Cogn Disord 1998; 9:2–7.
   Web of Science ®Google Scholar
• JL Cummings, JM Ringman. Metrifonate (Trichlorfon): A review of the pharmacology, pharmacokinetics and clinical experience with a new acetylcholinesterase inhibitor for Alzheimer's disease. Expert Opin Inv Drug 1999; 8:463–471.
   PubMedGoogle Scholar
• JC Morris, PA Cyrus, J Orazem, J Mas, F Bieber, BB Ruzicka, B Gulanski. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease. Neurology 1998; 50:1222–1230.
   PubMed Web of Science ®Google Scholar
• FY Sun, TE Schmid, E Schmid, A Baumgartner, ID Adler. Trichlorfon induces spindle disturbances in V79 cells and aneuploidy in male mouse germ cells. Mutagenesis 2000; 15:17–24.
   PubMed Web of Science ®Google Scholar
• MW Jann. Preclinical pharmacology of metrifonate. Pharmacotherapy 1998; 18:55–67.
   PubMed Web of Science ®Google Scholar
• LC Pettigrew, F Bieber, J Lettieri, DP Wermeling, FA Schitt, AJ Tikhtman, JW Ashford, CD Smith, DR Wekstein, WR Markesbery, J Orazem, BB Ruzicka, J Mas, B Gulanski. Pharmacokinetics, pharmacodynamics, and safety of metrifonate in patients with Alzheimer's disease. J Clin Pharmacol 1998; 38:236–245.
   PubMed Web of Science ®Google Scholar
• K Kuca, D Jun, K Musilek. Structural requirements of acetylcholinesterase reactivators. Mini Rev Med Chem 2006; 6:269–277.
   PubMed Web of Science ®Google Scholar
• J Wiesner, Z Kriz, K Kuca, D Jun, J Koca. Acetylcholinesterase – the structural similarities and differences. J Enz Inhib Med Chem 2007; 22:417–424.
   PubMed Web of Science ®Google Scholar
• K Kuca, J Kassa. A comparison of the ability of a new bispyridinium oxime-1-(4-hydroxyiminomethylpyridinium)-4-(4-carbamoylpyridinium)butane dibromide and currently used oximes to reactivate nerve agent-inhibited rat brain acetylcholinesterase by in vitro methods. J Enz Inhib Med Chem 2003; 18:529–535.
   PubMed Web of Science ®Google Scholar
• K Kuca, J Patocka. Reactivation of cyclosarin-inhibited rat brain acetylcholinesterase by pyridinium-oximes. J Enz Inhib Med Chem 2004; 19:39–43.
   PubMed Web of Science ®Google Scholar
• K Kuca, J Cabal, J Kassa. In vitro reactivation of sarin-inhibited brain acetylcholinesterase from different species by various oximes. J Enz Inhib Med Chem 2005; 20:227–232.
   PubMed Web of Science ®Google Scholar
• J Picha, K Kuca, M Kivala, M Kohout, J Cabal, F Liska. A new group of monoquaternary reactivators of acetylcholinesterase inhibited by nerve agents. J Enz Inhib Med Chem 2005; 20:233–237.
   PubMed Web of Science ®Google Scholar
• K Kuca, J Cabal, D Jun, J Bajgar, M Hrabinova. Potency of new structurally different oximes to reactivate cyclosarin-inhibited human brain acetylcholinesterase. J Enz Inhib Med Chem 2006; 21:663–666.
   PubMed Web of Science ®Google Scholar
• K Musilek, O Holas, K Kuca, D Jun, V Dohnal, M Dolezal. Synthesis of a novel series of non-symetrical bispyridinium compounds bearing a xylene linker and evaluation of their reactivation activity against tabun and paraoxon-inhibited acetylcholinesterase. J Enz Inhib Med Chem 2007; 23:70–76.
   Web of Science ®Google Scholar
• J Kassa, D Jun, K Kuca. A comparison of reactivating efficacy of newly developed oximes (K074, K075) and currently available oximes (obidoxime, HI-6) in cyclosarin-and tabun-poisoned rats. Enz Inhib Med Chem 2007; 22:297–300.
   PubMed Web of Science ®Google Scholar
• J Patocka, K Kuca, D Jun. Acetylcholinesterase and butyrylcholinesterase – important enzymes of human body. Acta Med (Hradec Kralove) 2004; 47:215–228.
   PubMedGoogle Scholar
• M Pohanka, D Jun, K Kuca. Photometric microplate assay for estimation of the efficacy of paraoxon-inhibited acetylcholinesterase reactivation. J Enz Inhib Med Chem 2007. In press
   Web of Science ®Google Scholar
• K Musilek, L Lipka, V Racakova, K Kuca, D Jun, V Dohnal, M Dolezal. New methods in synthesis of acetylcholinesterase reactivators and evaluation of their potency to reactivate cyclosarin-inhibited. AChE Chem Pap 2006; 60:48–51.
   Web of Science ®Google Scholar
• K Musilek, K Kuca, D Jun, V Dolezal. Synthesis of bispyridinium compounds bearing propane linker and evaluation of their reactivation activity against tabun – and paraoxon inhibited acetylcholinesterase. Lett Org Chem 2006; 3:831–835.
   Web of Science ®Google Scholar
• K Kuca, K Musilek, P Stodulka, J Marek, P Hanusova, D Jun, M Hrabinova, J Kassa, B Dolezal. Twelve different HI-6 salts and their potency to reactivate cyclosarin inhibited AChE in vitro. Lett Drug Des Discov 2007; 4:510–512.
   Web of Science ®Google Scholar
• K Kuca, J Bielavsky, J Cabal, J Kassa. Synthesis of a new reativator of tabun inhibited acetylcholinesterase. Bioorg Med Chem Lett 2003; 13:3545–3547.
   PubMed Web of Science ®Google Scholar
• NH Greig, DK Lahiri, K Sambamurti. Butyrylcholinesterase: An important new target in Alzheimer's disease therapy. Int Psychogeriatr 2002; 14:77–91.
   PubMed Web of Science ®Google Scholar
• A Shafferman, A Ordentlich, D Barak, D Stein, N Ariel, B Velan. Aging of phosphylated human acetylcholinesterase: Catalytic processes mediated by aromatic and residues of the active centre. Biochem J 1996; 318:833–840.
   PubMed Web of Science ®Google Scholar
• P Masson, PL Fortier, C Albaret, MT Froment, CF Barttels, O Lockridge. Aging of di-isopropyl-phosphorylated human butyrylcholinesterase. Biochem J 1997; 327:601–607.
   PubMed Web of Science ®Google Scholar
• M Pohanka, D Jun, K Kuca. Amperometric biosensor for evaluation of competitive cholinesterase inhibition by the reactivator HI-6. Anal Lett 2007; 40:2351–2359.
   Web of Science ®Google Scholar